AR089812A1 - Agente terapeutico para la diabetes mellitus - Google Patents
Agente terapeutico para la diabetes mellitusInfo
- Publication number
- AR089812A1 AR089812A1 ARP130100233A ARP130100233A AR089812A1 AR 089812 A1 AR089812 A1 AR 089812A1 AR P130100233 A ARP130100233 A AR P130100233A AR P130100233 A ARP130100233 A AR P130100233A AR 089812 A1 AR089812 A1 AR 089812A1
- Authority
- AR
- Argentina
- Prior art keywords
- group
- therapeutic agent
- formula
- mellitus diabetes
- therapeutic
- Prior art date
Links
- 206010012601 diabetes mellitus Diseases 0.000 title 1
- 239000003814 drug Substances 0.000 title 1
- 229940124597 therapeutic agent Drugs 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 1
- -1 2-phenylthiazole compound Chemical class 0.000 abstract 1
- 125000004195 4-methylpiperazin-1-yl group Chemical group [H]C([H])([H])N1C([H])([H])C([H])([H])N(*)C([H])([H])C1([H])[H] 0.000 abstract 1
- 239000004480 active ingredient Substances 0.000 abstract 1
- 125000003545 alkoxy group Chemical group 0.000 abstract 1
- 125000004453 alkoxycarbonyl group Chemical group 0.000 abstract 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 230000004153 glucose metabolism Effects 0.000 abstract 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 1
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 abstract 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 abstract 1
- 125000000587 piperidin-1-yl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 abstract 1
- 230000000069 prophylactic effect Effects 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/426—1,3-Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
Landscapes
- Health & Medical Sciences (AREA)
- Diabetes (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2012015351 | 2012-01-27 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR089812A1 true AR089812A1 (es) | 2014-09-17 |
Family
ID=48873581
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP130100233A AR089812A1 (es) | 2012-01-27 | 2013-01-25 | Agente terapeutico para la diabetes mellitus |
Country Status (15)
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104628673A (zh) * | 2015-02-10 | 2015-05-20 | 佛山市赛维斯医药科技有限公司 | 一类含叔丁基脒结构的腈基苯噻唑羧酸酰胺类化合物及用途 |
| CN104610188B (zh) * | 2015-02-10 | 2016-07-27 | 佛山市赛维斯医药科技有限公司 | 含苯基脒结构的腈基苯噻唑羧酸酰胺类化合物、其制备及用途 |
| CN104628671B (zh) * | 2015-02-10 | 2016-04-13 | 佛山市赛维斯医药科技有限公司 | 含苯基脒结构的硝基苯噻唑羧酸酰胺类化合物及用途 |
| CN104628672A (zh) * | 2015-02-10 | 2015-05-20 | 佛山市赛维斯医药科技有限公司 | 一类含苯基脒结构的烷氧苯基噻唑羧酸酰胺类化合物及用途 |
| CN104610190B (zh) * | 2015-02-10 | 2016-08-17 | 佛山市赛维斯医药科技有限公司 | 一类含环丙基脒结构的卤代苯基噻唑羧酸酰胺类化合物及用途 |
| KR102473677B1 (ko) * | 2015-08-17 | 2022-12-02 | 삼성디스플레이 주식회사 | 액정 표시 장치 |
| JP6732004B2 (ja) | 2016-02-19 | 2020-07-29 | 国立大学法人鳥取大学 | 認知症治療薬または予防薬 |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK0513379T3 (da) | 1990-11-30 | 1996-09-30 | Teijin Ltd | 2-Arylthiazolderivater og farmaceutisk præparat indeholdende sådanne |
| HUP9902721A2 (hu) * | 1997-11-25 | 1999-12-28 | The Procter & Gamble Co. | Tömény textillágyító készítmény és ehhez alkalmazható magas telítetlenségű textillágyító vegyület |
| US20050074442A1 (en) * | 2002-03-13 | 2005-04-07 | Natarajan Ranganathan | Compositions and methods for augmenting kidney function |
| WO2006012438A2 (en) * | 2004-07-21 | 2006-02-02 | University Of Florida Research Foundation, Inc. | Compositions and methods for treatment and prevention of insulin resistance |
| JP2009501795A (ja) * | 2005-07-21 | 2009-01-22 | ユニバーシティ オブ フロリダ リサーチファウンデーション インコーポレイティッド | 高尿酸血に関連する健康状態の治療及び予防のための組成物及び方法 |
| JP5242393B2 (ja) | 2005-08-03 | 2013-07-24 | タケダ ファーマシューティカルズ ユー．エス．エー． インコーポレイティド | 高血圧症の治療方法 |
| EP1957064A4 (en) * | 2005-11-21 | 2010-01-06 | Tap Pharmaceutical Prod Inc | TREATMENT OF QT INTERVAL EXTENSION AND RELEVANT DISEASES |
| JP2007210978A (ja) * | 2006-02-13 | 2007-08-23 | Hiroshima Univ | 耐糖能障害、ｉｉ型糖尿病、高脂血症、メタボリックシンドローム、内臓脂肪型肥満、脂肪肝または非アルコール性脂肪性肝炎の予防・治療剤 |
| JP2010509372A (ja) | 2006-11-13 | 2010-03-25 | タケダ・フアーマシユーテイカルズ・ノース・アメリカ・インコーポレイテツド | キサンチン酸化還元酵素阻害剤を使用する腎機能保持方法 |
| US8084483B2 (en) * | 2007-11-27 | 2011-12-27 | Ardea Biosciences, Inc. | Compounds and compositions and methods of use |
| CN102015726B (zh) * | 2008-03-31 | 2014-07-23 | C&C新药研究所 | 杂环衍生物 |
| CA2722624C (en) * | 2008-04-30 | 2017-03-21 | Wellstat Therapeutics Corporation | Tetrazole compounds for reducing uric acid |
| US8791077B2 (en) * | 2008-05-22 | 2014-07-29 | Astrazeneca Ab | Method for treating hyperuricemia employing an SGLT2 inhibitor and composition containing same |
| EP2398319A4 (en) * | 2008-10-19 | 2012-11-14 | Richard J Johnson | THERAPEUTIC COMPOSITIONS AND METHODS FOR TREATING CHRONIC NEPHITIA ASSOCIATED WITH METABOLIC IMBALANCE |
| EP2470268A4 (en) * | 2009-08-24 | 2012-12-26 | Wound Man Pty Ltd | PURING-ORIENTED DIAGNOSIS AND THERAPY OF WOUNDS |
| JP5865904B2 (ja) * | 2010-06-16 | 2016-02-17 | タケダ ファーマシューティカルズ ユー．エス．エー． インコーポレイティド | キサンチンオキシドレダクターゼ阻害剤またはキサンチンオキシダーゼ阻害剤の新規の調節放出剤形 |
| KR20130088755A (ko) * | 2010-06-25 | 2013-08-08 | 데이진 화-마 가부시키가이샤 | 서방성 고혈압 및 신 기능 장애 치료제 |
-
2013
- 2013-01-25 RU RU2014134845A patent/RU2014134845A/ru not_active Application Discontinuation
- 2013-01-25 MX MX2014008484A patent/MX2014008484A/es unknown
- 2013-01-25 IN IN5972DEN2014 patent/IN2014DN05972A/en unknown
- 2013-01-25 TW TW102102886A patent/TW201334779A/zh unknown
- 2013-01-25 US US14/372,961 patent/US20150005506A1/en not_active Abandoned
- 2013-01-25 WO PCT/JP2013/051627 patent/WO2013111870A1/ja not_active Ceased
- 2013-01-25 EP EP13740913.2A patent/EP2808018B1/en not_active Not-in-force
- 2013-01-25 JP JP2013555326A patent/JP5924699B2/ja not_active Expired - Fee Related
- 2013-01-25 HK HK15101890.2A patent/HK1201209A1/xx unknown
- 2013-01-25 CA CA2862602A patent/CA2862602A1/en not_active Abandoned
- 2013-01-25 BR BR112014017902A patent/BR112014017902A2/pt not_active IP Right Cessation
- 2013-01-25 KR KR1020147020342A patent/KR20140134266A/ko not_active Withdrawn
- 2013-01-25 AU AU2013212865A patent/AU2013212865A1/en not_active Abandoned
- 2013-01-25 CN CN201380006730.6A patent/CN104066430A/zh active Pending
- 2013-01-25 AR ARP130100233A patent/AR089812A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP2808018A1 (en) | 2014-12-03 |
| BR112014017902A2 (pt) | 2017-08-22 |
| RU2014134845A (ru) | 2016-03-20 |
| CN104066430A (zh) | 2014-09-24 |
| JPWO2013111870A1 (ja) | 2015-05-11 |
| AU2013212865A1 (en) | 2014-08-14 |
| HK1201209A1 (en) | 2015-08-28 |
| EP2808018B1 (en) | 2018-03-14 |
| WO2013111870A1 (ja) | 2013-08-01 |
| IN2014DN05972A (cg-RX-API-DMAC7.html) | 2015-06-26 |
| CA2862602A1 (en) | 2013-08-01 |
| JP5924699B2 (ja) | 2016-05-25 |
| KR20140134266A (ko) | 2014-11-21 |
| TW201334779A (zh) | 2013-09-01 |
| US20150005506A1 (en) | 2015-01-01 |
| MX2014008484A (es) | 2014-10-14 |
| EP2808018A4 (en) | 2015-07-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR093093A1 (es) | Tratamientos y profilaxis para el sindrome de lisis tumoral | |
| AR092661A1 (es) | Inhibidor de quinasas reordenadas durante la transfeccion (ret) y un metodo para identificar un paciente sensible a un compuesto representado por la formula (1) | |
| AR089812A1 (es) | Agente terapeutico para la diabetes mellitus | |
| DK2970216T3 (da) | Biarylamidforbindelser som kinaseinhibitorer | |
| MX2020003415A (es) | Compuestos de benzoxacepina oxazolidinona y métodos de uso. | |
| EA201690020A1 (ru) | Применение производных пиразолопиридина для лечения рака мочевого пузыря | |
| EA201492023A1 (ru) | Регуляторы пути комплемента и их применение | |
| JO3091B1 (ar) | مشتقات حمض 3- فنيل بروبيونيك متفرعة واستخداماتها | |
| CR20120448A (es) | Compuesto heterocíclico | |
| EA201690223A1 (ru) | Ингибиторы фактора в комплемента на основе производных пиперидинилиндола и их применение | |
| PH12015502628A1 (en) | Pyrazolopyrrolidine derivatives and their use in the treatment of disease | |
| MX2015016344A (es) | Derivados de imidazo-pirrolidinona y su uso en el tratamiento de enfermedades. | |
| NZ703989A (en) | Alkoxy pyrazoles as soluble guanylate cyclase activators | |
| UY32816A (es) | Formulación farmacéutica a base de 1-[2-(2,1,3-benzotiadiazol-5-ilamino)-6(2,6-diclorofenil)-pirido[2,3-d] pirimidin-7-il]-3-tert-butil-uréa | |
| DOP2006000170A (es) | Nuevos derivados de espirocromanona | |
| EA201590200A1 (ru) | Модуляторы пути активации комплемента и их применение | |
| MX2015006039A (es) | Derivados de pirimidin-2, 4-diamina para el tratamiento de cancer. | |
| CO6491060A2 (es) | Compuestos y composiciones para el tratamiento de enfermedades parasitarias | |
| MX2015002669A (es) | Metodos de administracion de tratamiento con pirfenidona. | |
| MX2015016421A (es) | Derivados de pirazolo-pirrolidin-4-ona como inhibidores de bet y su uso en el tratamiento de enfermedades. | |
| PH12014501967B1 (en) | Benzodioxanes in combination with other actives for inhibiting leukotriene production | |
| MX2020005736A (es) | Derivados de glutarimida, uso de los mismos, composicion farmaceutica basada en los mismos y metodos para producir derivados de glutarimida. | |
| CU20150084A7 (es) | Derivados del ácido 4-((1,1) bisfenil -4-il)-3-(3-fosfonopropanamido)butanoico,activo como inhibidores de nep(endopeptidasa neutral) | |
| WO2014107730A3 (en) | Use of fatty acid niacin conjugates for treating diseases | |
| AR088287A1 (es) | Agente terapeutico y agente preventivo para la enfermedad desmielinizante |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |